Literature DB >> 20385910

Comparing fludeoxyglucose F18-PET assessment of regional cerebral glucose metabolism and [11C]dihydrotetrabenazine-PET in evaluation of early dementia and mild cognitive impairment.

Roger L Albin1, Robert A Koeppe, James F Burke, Bruno Giordani, Michael R Kilbourn, Sid Gilman, Kirk A Frey.   

Abstract

OBJECTIVE: To compare assessment of regional cerebral metabolic changes with [(11)C]dihydrotetrabenazine (DTBZ)-positron emission tomography (PET) measurement of regional cerebral blood flow (K(1)) and fludeoxyglucose F18 (FDG)-PET measurement of regional cerebral glucose uptake (CMR(glc)) in a clinically representative sample of subjects with mild dementia and mild cognitive impairment (MCI).
DESIGN: [(11)C]Dihydrotetrabenazine-PET K(1) and FDG-PET CMR(glc) measurements were performed.
SETTING: University-based cognitive disorders clinic. PARTICIPANTS: Fifty subjects with either mild dementia (Mini-Mental State Examination score > or = 18) or MCI. Their results were compared with those of 80 normal control subjects. MAIN OUTCOME MEASURES: The DTBZ-PET regional K(1) and FDG-PET CMR(glc) measurements were compared with standard correlation analysis. The overall patterns of DTBZ-PET K(1) and FDG-PET CMR(glc) deficits were assessed with stereotaxic surface projections (SSPs) of parametric images.
RESULTS: The DTBZ-PET regional K(1) and FDG-PET CMR(glc) measurements were highly correlated, both within and between subjects. The SSP maps of deficits in DTBZ-PET regional K(1) and FDG-PET CMR(glc) measurements were markedly similar. The DTBZ-PET K(1) SSP maps exhibited a mild decrease in sensitivity relative to FDG-PET CMR(glc) maps.
CONCLUSIONS: Both DTBZ-PET K(1) and FDG-PET CMR(glc) measurements provide comparable information in assessment of regional cerebral metabolic deficits in mild dementia and MCI. Blood flow measures can assess regional cerebral metabolism deficits accurately in mild dementia and MCI. Blood flow assessments of regional cerebral metabolic deficits can be combined with tracer binding results to improve utility of PET imaging in mild dementia and MCI.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20385910      PMCID: PMC3141210          DOI: 10.1001/archneurol.2010.34

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  73 in total

1.  Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.

Authors:  M A Piggott; E F Marshall; N Thomas; S Lloyd; J A Court; E Jaros; D Burn; M Johnson; R H Perry; I G McKeith; C Ballard; E K Perry
Journal:  Brain       Date:  1999-08       Impact factor: 13.501

2.  Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease?

Authors:  G Chételat; B Desgranges; V de la Sayette; F Viader; F Eustache; J-C Baron
Journal:  Neurology       Date:  2003-04-22       Impact factor: 9.910

3.  Imaging amyloid deposition in Lewy body diseases.

Authors:  S N Gomperts; D M Rentz; E Moran; J A Becker; J J Locascio; W E Klunk; C A Mathis; D R Elmaleh; T Shoup; A J Fischman; B T Hyman; J H Growdon; K A Johnson
Journal:  Neurology       Date:  2008-09-16       Impact factor: 9.910

4.  Computed tomography and positron emission transaxial tomography evaluations of normal aging and Alzheimer's disease.

Authors:  M J de Leon; S H Ferris; A E George; B Reisberg; D R Christman; I I Kricheff; A P Wolf
Journal:  J Cereb Blood Flow Metab       Date:  1983-09       Impact factor: 6.200

5.  Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer's disease and frontotemporal dementia.

Authors:  A R Varma; J S Snowden; J J Lloyd; P R Talbot; D M Mann; D Neary
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-02       Impact factor: 10.154

6.  FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease.

Authors:  Norman L Foster; Judith L Heidebrink; Christopher M Clark; William J Jagust; Steven E Arnold; Nancy R Barbas; Charles S DeCarli; R Scott Turner; Robert A Koeppe; Roger Higdon; Satoshi Minoshima
Journal:  Brain       Date:  2007-08-18       Impact factor: 13.501

7.  Anatomic standardization: linear scaling and nonlinear warping of functional brain images.

Authors:  S Minoshima; R A Koeppe; K A Frey; D E Kuhl
Journal:  J Nucl Med       Date:  1994-09       Impact factor: 10.057

Review 8.  PET studies in dementia.

Authors:  Karl Herholz
Journal:  Ann Nucl Med       Date:  2003-04       Impact factor: 2.668

9.  Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis.

Authors:  S Minoshima; K A Frey; N L Foster; D E Kuhl
Journal:  J Comput Assist Tomogr       Date:  1995 Jul-Aug       Impact factor: 1.826

10.  Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease.

Authors:  Yi Li; Juha O Rinne; Lisa Mosconi; Elizabeth Pirraglia; Henry Rusinek; Susan DeSanti; Nina Kemppainen; Kjell Någren; Byeong-Chae Kim; Wai Tsui; Mony J de Leon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-06-20       Impact factor: 9.236

View more
  2 in total

1.  Post-Mortem evaluation of amyloid-dopamine terminal positron emission tomography dementia classifications.

Authors:  Roger L Albin; Amanda Fisher-Hubbard; Krithika Shanmugasundaram; Robert A Koeppe; James F Burke; Sandra Camelo-Piragua; Andrew P Lieberman; Bruno Giordani; Kirk A Frey
Journal:  Ann Neurol       Date:  2015-08-25       Impact factor: 10.422

Review 2.  Potential neuroimaging biomarkers of pathologic brain changes in Mild Cognitive Impairment and Alzheimer's disease: a systematic review.

Authors:  Qingwei Ruan; Grazia D'Onofrio; Daniele Sancarlo; Zhijun Bao; Antonio Greco; Zhuowei Yu
Journal:  BMC Geriatr       Date:  2016-05-16       Impact factor: 3.921

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.